Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2022 05 05T140844Z 1 LYNXNPEI440OX RTROPTP 4 HEALTH CORONAVIRUS SPAHN - Business Express
FILE PHOTO: Employees in clean room work in the production of the Allergopharma plant in Reinbek near Hamburg, Germany, April 30, 2021, as the they started the Pfizer/BioNTech Covid-19 vaccine production. Christian Charisius/Pool via REUTERS

EU regulator hopes to approve COVID variant-adapted vaccines by autumn

(Reuters) – The European Union’s drug regulator said on Thursday it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September.

“Our priority is to ensure that adaptive vaccines are possibly approved by September at the latest to be ready for the rollout of new immunisation campaigns in the EU in the autumn,” said Marco Cavaleri, head of biological health threats and vaccines strategy at the European Medicines Agency (EMA).

“This would allow manufacturers to adjust their production lines accordingly.”

The mRNA vaccines, made by Pfizer-BioNTech and Moderna, are the furthest along, and clinical trials are ongoing.

Vaccine developers are investigating whether shots that target just one variant offer advantages over vaccines that target two variants, Cavaleri added, noting trial data was expected to come in over the next coupe of months.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Moderna is developing a potential next generation booster targeted at both the Omicron variant as well as the original strain of the coronavirus in the hope of producing broader protection. It expects first trial data in June.

Meanwhile, at the end of March, BioNTech and Pfizer broadened their original trial programme that prioritised a booster shot that targets only Omicron to also test a shot targeting Omicron and the original version of the coronavirus.

According to Cavaleri, about half of all EU citizens are fully vaccinated and boosted, while 15% of those over 18 have not received even one vaccine shot.


(Reporting by Natalie Grover and Ludwig Burger; Editing by Toby Chopra and Mark Potter)

Recent Post: